{"id":2638,"date":"2017-01-23T10:58:32","date_gmt":"2017-01-23T09:58:32","guid":{"rendered":"http:\/\/semmelweis.hu\/patologia1\/?page_id=2638"},"modified":"2025-12-09T11:59:55","modified_gmt":"2025-12-09T10:59:55","slug":"aramlasi-citometriai-munkacsoport","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/patologia1\/kutatas\/aramlasi-citometriai-munkacsoport\/","title":{"rendered":"\u00c1raml\u00e1si citometriai munkacsoport"},"content":{"rendered":"

(Dr. Barna G\u00e1bor<\/a>, Kov\u00e1csn\u00e9 Dr. M\u00e1rk \u00c1gnes, Dr. Szal\u00f3ki G\u00e1bor, Dr. Kriston Csilla)<\/strong><\/p>\n

A munkacsoport tev\u00e9kenys\u00e9ge \u00e9s f\u0151bb eredm\u00e9nyei:<\/strong><\/p>\n

Munkacsoportunk f\u0151 c\u00e9lkit\u0171z\u00e9se a B-sejtes lymphom\u00e1k, leuk\u00e9mi\u00e1k differenci\u00e1l diagnosztik\u00e1j\u00e1nak fejleszt\u00e9se, prognosztikus faktorok, valamint a tumorsejtek \u00e9s a mikrok\u00f6rnyezet kapcsolat\u00e1nak kutat\u00e1sa \u00e1raml\u00e1s citometriai, molekul\u00e1ris \u00e9s sejtbiol\u00f3giai m\u00f3dszerekkel.<\/p>\n

Laborat\u00f3riumunkban lymphom\u00e1k, leuk\u00e9mi\u00e1k immunfenotipiz\u00e1l\u00e1s\u00e1t v\u00e9gezz\u00fck a hozz\u00e1nk \u00e9rkez\u0151 v\u00e9r \u00e9s csontvel\u0151 aspir\u00e1tum mint\u00e1kon. Ehhez k\u00f6t\u00f6d\u0151en v\u00e9gezz\u00fck a kutat\u00e1sainkat is.<\/p>\n

A lymphom\u00e1s, leuk\u00e9mi\u00e1s megbeteged\u00e9sek sz\u00e1ma \u00e9vr\u0151l \u00e9vre n\u00f6vekszik. Manaps\u00e1g ezen betegs\u00e9gek kezel\u00e9se m\u00e1r legt\u00f6bbsz\u00f6r c\u00e9lzott ter\u00e1pi\u00e1k seg\u00edts\u00e9g\u00e9vel t\u00f6rt\u00e9nik. Ennek ellen\u00e9re gyakran ezek a ter\u00e1pi\u00e1k is hat\u00e1stalanok, mert ugyan a perif\u00e9ri\u00e1n kering\u0151 sejtek elpusztulnak a kezel\u00e9sek hat\u00e1s\u00e1ra, a csontvel\u0151ben vagy a nyirokcsom\u00f3kban megb\u00fav\u00f3 tumorsejtek az \u0151ket t\u00e1mogat\u00f3 mikrok\u00f6rnyezet sejtjeinek seg\u00edts\u00e9g\u00e9vel t\u00fal\u00e9lnek \u00e9s \u00fajra tudj\u00e1k termelni a tumorsejteket.<\/p>\n

Kutat\u00e1sainkban vizsg\u00e1ljuk a lymphoma \u00e9s leuk\u00e9mia sejtek immunfenot\u00edpus\u00e1t. In vitro sejtkult\u00far\u00e1kban, csontvel\u0151i str\u00f3ma sejtekkel kokult\u00far\u00e1kban a beteg mint\u00e1kb\u00f3l izol\u00e1lt tumorsejtek t\u00fal\u00e9l\u00e9s\u00e9t, prolifer\u00e1ci\u00f3j\u00e1t, citokin termel\u00e9s\u00e9t m\u00e9rj\u00fck \u00e9s \u00f6sszevetj\u00fck a k\u00fcl\u00f6nb\u00f6z\u0151 felsz\u00edni vagy intracellul\u00e1ris feh\u00e9rj\u00e9k expresszi\u00f3j\u00e1val, m\u00e1s m\u00f3dszerekkel kimutatott (molekul\u00e1ris, FISH) prognosztikus faktorokkal, mut\u00e1ci\u00f3kkal. Az \u00edgy kapott adatok seg\u00edts\u00e9g\u00e9vel pr\u00f3b\u00e1ljuk felt\u00e9rk\u00e9pezni a tumorsejtek \u00e9s a mikrok\u00f6rnyezet\u00fck kapcsolat\u00e1t, valamint a k\u00fcl\u00f6nb\u00f6z\u0151 felsz\u00edni molekul\u00e1k szerep\u00e9t ezekben a folyamatokban.<\/p>\n

 <\/p>\n

Jelenlegi kutat\u00e1si t\u00e9m\u00e1k:<\/strong><\/p>\n

CD49f izoform\u00e1k vizsg\u00e1lata B-sejtes akut lymphoblasztos leuk\u00e9mi\u00e1ban<\/p>\n

Myeloma multiplex MRD m\u00e9r\u00e9se \u00faj gener\u00e1ci\u00f3s \u00e1raml\u00e1si citometri\u00e1val<\/p>\n

CD180 expresszi\u00f3 vizsg\u00e1lata akut leuk\u00e9mi\u00e1kban<\/p>\n

T-sejt alpopul\u00e1ci\u00f3k v\u00e1ltoz\u00e1sa mezigdomiddal kezelt myeloma multiplexes betegekben<\/p>\n

A venetoclax-obinutuzumab ter\u00e1pia hat\u00e9konys\u00e1g\u00e1nak \u00e9rt\u00e9kel\u00e9se \u00e1raml\u00e1si citometri\u00e1val kr\u00f3nikus limfocit\u00e1s leuk\u00e9mi\u00e1ban (CLL).<\/p>\n

FLT-3 \u00e9s tirozin kin\u00e1z inhibitorok hat\u00e1s\u00e1nak vizsg\u00e1lata az AML sejtek t\u00fal\u00e9l\u00e9s\u00e9re<\/p>\n

 <\/p>\n

A laborat\u00f3riumban tal\u00e1lhat\u00f3 \u00e1raml\u00e1si citom\u00e9terek:<\/strong><\/p>\n

Navios (Beckman Coulter) \u2013 2 l\u00e9zer, 8 fluoreszcens param\u00e9ter<\/p>\n

FACSLyric (Becton Dickinson)\u2013 3 l\u00e9zer, 10 fluoreszcens param\u00e9ter<\/p>\n

DX Flex (Beckman Coulter) \u2013 3 l\u00e9zer, 13 fluoreszcens param\u00e9ter<\/p>\n

\"\"<\/p>\n

\"\"<\/p>\n

Publik\u00e1ci\u00f3k:<\/strong><\/p>\n

    \n
  1. Barna G, Szal\u00f3ki G, M\u00e1rk \u00c1, Hunyadi A, Kriston Cs,<\/strong>. CD86 , the double agent: Significance of CD86 expression in B\u2010cell malignancies Int J Cancer. 2025 Nov 1;157(9):1772-1780. doi: 10.1002\/ijc.70028. Epub 2025 Jul 10.<\/li>\n
  2. Szal\u00f3ki G<\/strong>, Szepesi \u00c1, T\u00e1rk\u00e1nyi I, M\u00e1rk \u00c1, Kriston C, Hunyadi A<\/strong>, M\u00f3zes R, Barna G<\/strong>.Case Report: Flow cytometric differential diagnosis of a peripheral T-cell lymphoma, NOS with complete loss of CD45 and dim expression of CD3. Pathol Oncol Res. 2025 May 29;31:1612095. doi: 10.3389\/pore.2025.1612095. eCollection 2025.<\/li>\n
  3. Hunyadi A, Kriston Cs, Szal\u00f3ki G.,<\/strong> P\u00e9terffy B., Egyed B, Szepesi \u00c1, Tim\u00e1r B, Erd\u00e9lyi D, Csan\u00e1di K, Kutszegi N, Barna G.<\/strong> The significance of CD49f expression in pediatric B-cell acute lymphoblastic leukemia AMERICAN JOURNAL OF CLINICAL PATHOLOGY 163 : 2 pp. 169-177. , 9 p. (2025)<\/li>\n
  4. Czeti \u00c1, Sashalmi S, Tak\u00e1cs F, Szal\u00f3ki G, Kriston C,<\/strong> Varga G, Farkas P, Hamed A, M\u00e1rk \u00c1, Barna G.<\/strong> Investigating the effect of immunomagnetic separation on the immunophenotype and viability of plasma cells in plasma cell disorders. Pathol Oncol Res. 2024 Oct 18;30:1611882. doi: 10.3389\/pore.2024.1611882. eCollection 2024.<\/li>\n
  5. Tak\u00e1cs F<\/strong>, Kotmayer L, Czeti \u00c1, Szal\u00f3ki G,<\/strong> L\u00e1szl\u00f3 T,Mikala G, M\u00e1rk \u00c1, <\/strong>Masszi A, Farkas P, Plander M, Weisinger J, Demeter J, Fekete S, Szerafin L, De\u00e1k BM, Szaleczky E, Sul\u00e1k A, Borb\u00e9nyi Z, Barna G. <\/strong>Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry. Pathol Oncol Res. 2022;28: 1610659. Published online 2022 Sep 21. doi: 10.3389\/pore.2022.1610659<\/li>\n
  6. Czeti \u00c1, Szal\u00f3ki G,<\/strong> Varga G, Szita VR, Koml\u00f3si ZI, Tak\u00e1cs F, M\u00e1rk \u00c1,<\/strong> Tim\u00e1r B, Matolcsy A, Barna G. <\/strong>Limitations of VS38c labeling in the detection of plasma cell myeloma by flow cytometry. Cytometry A. 2022 Feb;101(2):159-166. doi: 10.1002\/cyto.a.24488. Epub 2021 Jul 30.<\/li>\n
  7. Kriston C, <\/strong>Hern\u00e1df\u0151i M, Plander M, M\u00e1rk \u00c1, Tak\u00e1cs F, Czeti \u00c1, Szal\u00f3ki G,<\/strong> Szab\u00f3 O, Matolcsy A, Barna G. <\/strong>Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia. Hematol Oncol. 2021 Oct;39(4):513-520. doi: 10.1002\/hon.2888. Epub 2021 May 20.<\/li>\n
  8. Tak\u00e1cs F, Tolnai-Kriston C,<\/strong> Hern\u00e1df\u0151i M, Szab\u00f3 O, Szal\u00f3ki G,<\/strong> Szepesi \u00c1, Czeti \u00c1,<\/strong> Matolcsy A, Barna G. <\/strong>The Effect of CD86 Expression on the Proliferation and the Survival of CLL Cells. Pathol Oncol Res. 2019 Apr;25(2):647-652. doi: 10.1007\/s12253-018-0512-7. Epub 2018 Nov 8.<\/li>\n
  9. Kriston C<\/strong>, Plander M, M\u00e1rk \u00c1,<\/strong> Sebesty\u00e9n A, Bugyik E, Matolcsy A, Barna G<\/strong>. In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment. Ann Hematol. 2018 Jun 28. doi: 10.1007\/s00277-018-3410-x.<\/li>\n
  10. M\u00e1rk \u00c1<\/strong>, Varga G, Tim\u00e1r B, Kriston C<\/strong>, Szab\u00f3 O, De\u00e1k L, Matolcsy A, Barna G<\/strong>. The effect of microenvironmental factors on the development of myeloma cells. Hematol Oncol. 2016 Oct 21. doi: 10.1002\/hon.2354.<\/li>\n
  11. Kriston C<\/strong>, B\u00f6d\u00f6r C, Szenthe K, B\u00e1n\u00e1ti F, B\u00e1nkuti B, Csernus B, Reiniger L, Csomor J, Matolcsy A, Barna G<\/strong>. Low CD23 expression correlates with high CD38 expression and the presence of trisomy 12 in CLL. Hematol Oncol. 2015 Jun 29. doi: 10.1002\/hon.2244.<\/li>\n
  12. Barna G<\/strong>, Mihalik R, Tim\u00e1r B, T\u00f6mb\u00f6l J, Csende Z, Sebesty\u00e9n A, B\u00f6d\u00f6r C, Csernus B, Reiniger L, Pet\u00e1k I, Matolcsy A. ROR1 expression is not a unique marker of CLL. Hematol Oncol. 2011 Mar;29(1):17-21. doi: 10.1002\/hon.948.<\/li>\n<\/ol>\n

     <\/p>\n

    A munkacsoport tagjai:<\/strong><\/p>\n

    Dr. Barna G\u00e1bor, tudom\u00e1nyos tan\u00e1csad\u00f3<\/p>\n

    Kov\u00e1csn\u00e9 Dr. M\u00e1rk \u00c1gnes, tudom\u00e1nyos munkat\u00e1rs<\/p>\n

    Dr. Szal\u00f3ki G\u00e1bor, tudom\u00e1nyos munkat\u00e1rs<\/p>\n

    Dr. Tolnai-Kriston Csilla, tudom\u00e1nyos munkat\u00e1rs<\/p>\n

    Dr. Hunyadi Anna, PhD hallgat\u00f3<\/p>\n

    Arany\u00e1s Mikl\u00f3s, biol\u00f3gus<\/p>\n

    Jahoda Brigitta, biol\u00f3gus<\/p>\n

    \"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

    ( Dr. Barna G\u00e1bor<\/a> , Kov\u00e1csn\u00e9 Dr. M\u00e1rk \u00c1gnes, Dr. Szal\u00f3ki G\u00e1bor, Dr. Kriston Csilla) A munkacsoport tev\u00e9kenys\u00e9ge \u00e9s f\u0151bb eredm\u00e9nyei: Munkacsoportunk f\u0151 c\u00e9lkit\u0171z\u00e9se a B-sejtes lymphom\u00e1k, leuk\u00e9mi\u00e1k differenci\u00e1l diagnosztik\u00e1j\u00e1nak fejleszt\u00e9se, prognosztikus faktorok, valamint a tumorsejtek \u00e9s a mikrok\u00f6rnyezet kapcsolat\u00e1nak kutat\u00e1sa \u00e1raml\u00e1s citometriai, molekul\u00e1ris \u00e9s sejtbiol\u00f3giai m\u00f3dszerekkel. Laborat\u00f3riumunkban lymphom\u00e1k, leuk\u00e9mi\u00e1k immunfenotipiz\u00e1l\u00e1s\u00e1t v\u00e9gezz\u00fck a hozz\u00e1nk \u00e9rkez\u0151 v\u00e9r \u00e9s csontvel\u0151 …<\/p>\n","protected":false},"author":101021,"featured_media":0,"parent":42,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-2638","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages\/2638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/users\/101021"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/comments?post=2638"}],"version-history":[{"count":8,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages\/2638\/revisions"}],"predecessor-version":[{"id":8880,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages\/2638\/revisions\/8880"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/pages\/42"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/media?parent=2638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/categories?post=2638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/patologia1\/wp-json\/wp\/v2\/tags?post=2638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}